Artivion To Present New Clinical Data For On-X Aortic Heart Valve And AMDS At 104th AATS Annual Meeting

Artivion, Inc. Common Stock +2.56%

Artivion, Inc. Common Stock




5-Year Real-World Safety and Efficacy Data from On-X Aortic Heart Valve Low INR Post-Market Study Demonstrate Even Better Patient Outcomes Than Predicted by the PROACT IDE Study

Late-Breaking 30-Day Data from AMDS PERSEVERE Trial Demonstrate Positive Aortic Remodeling Outcomes and Zero DANE Tears

Every question you ask will be answered
Scan the QR code to contact us
Also you can contact us via